Sinemet CR is a prescription medication licensed to treat Parkinson's disease and Parkinson-like symptoms caused by certain conditions. It helps to increase the levels of dopamine in the brain, which may be responsible for many of the symptoms of Parkinson's disease. The tablets are specially designed to slowly release the medication to prevent fluctuations in the level of carbidopa and levodopa in the blood.
Interested in a Discount on Sinemet CR?
Enter your email address to see if eMedTV's free DiscountRx service has a program that could help you save on your prescription(s).
Enter Your Email Address
Thank you!Thank you for your interest in DiscountRx from eMedTV. An email has been sent to the address you provided. Please follow the link within that email to see what offers may be available.
Sinemet® CR (carbidopa-levodopa CR) is a prescription medication most frequently used to treat Parkinson's disease. This medication is also approved to treat parkinsonism (Parkinson-like symptoms) due to encephalitis (inflammation or infection of the brain), manganese poisoning, or carbon monoxide poisoning. It is specially designed to slowly release the medication over four to six hours, which helps to prevent fluctuations in the level of carbidopa and levodopa in the blood.
Sinemet CR is made by Mylan Pharmaceuticals, Inc., for Merck & Co., Inc.
Sinemet CR contains two different active ingredients: levodopa and carbidopa. The levodopa is the "real" ingredient in Sinemet CR that works for Parkinson's disease. The carbidopa does not have any direct effects on Parkinson's disease when used alone, but it does help to make the levodopa more effective.
Dopamine deficiency (caused by a loss of dopamine-producing cells) in certain parts of the brain may be responsible for many of the symptoms of Parkinson's disease. Although it would make sense to give dopamine to help treat Parkinson's, this does not work, as dopamine cannot cross the blood-brain barrier to reach the brain. Levodopa is a precursor of dopamine, which means that the body can use it to make dopamine. Unlike dopamine, levodopa crosses the blood-brain barrier.
Levodopa is almost always given in combination with carbidopa. Carbidopa delays the conversion of levodopa into dopamine until it reaches the brain, preventing or diminishing some of the side effects that often accompany levodopa therapy. Carbidopa also reduces the amount of levodopa needed for Parkinson's disease treatment.